Catalytic antibodies in clinical and experimental pathology: Human and mouse models

Journal of Immunological Methods

Volumn 269, Issue 1-2, 2002, Pages 197-211

  Ponomarenko, Natalya A ^a   Durova, Oxana M ^b   Vorobiev, Ivan I ^a   Aleksandrova, Elena S ^a   Telegin, Georgy B ^a   Chamborant, Olga G ^a   Sidorik, Lyudmila L ^c   Suchkov, Sergei V ^b   Alekberova, Zemfira S ^d   Gnuchev, Nikolay V ^e   Gabibov, Alexander G ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b M F VLADIMIRSKY MOSCOW REGIONAL RESEARCH CLINICAL INSTITUTE   (Russian Federation)

^c INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

^d V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^e INSTITUTE OF GENE BIOLOGY   (Russian Federation)

Author keywords

Autoimmune mice; Catalytic antibodies; DNA hydrolyzing abzymes (DNA abzymes); Fluorescence assay technique (FAT); MRL lpr lpr; Multiple sclerosis (MS); NZBxNZW; Proteolytic abzymes (protabzymes); SJL J; Systemic lupus erythematosus (SLE)

Indexed keywords

ANTIGEN; AUTOANTIBODY; CATALYTIC ANTIBODY; DNA; IMMUNOGLOBULIN G; MUSCLE PROTEIN; MYELIN BASIC PROTEIN; MYOSIN; POLYCLONAL ANTIBODY;

ADULT; AGE; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BLOOD ANALYSIS; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOASSAY; MOUSE; MOUSE STRAIN; MULTIPLE SCLEROSIS; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN HYDROLYSIS; PROTEIN PURIFICATION; PROTEIN TARGETING; SKELETAL MUSCLE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, CATALYTIC; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; DNA; ENDOPEPTIDASES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED MRL LPR; MULTIPLE SCLEROSIS;

ANIMALIA; SCLERODERMA;

EID: 0036837368     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(02)00324-1     Document Type: Article

References (39)

1. Avalle B., Thomas D., Friboulet A. Functional mimicry: elicitation of a monoclonal anti-idiotypic antibody hydrolyzing beta-lactams. FASEB J. 12:1998;1055.
2. Bernard C.C., Carnegie P.R. Experimental autoimmune encephalomyelitis in mice: immunologic response to mouse spinal cord and myelin basic proteins. J. Immunol. 114:1975;1537.
3. Blaes F., Klotz M., Huwer H., Straub U., Kalweit G., Schimrigk K., Schafers H.J. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann. Thorac. Surg. 69:2000;254.
4. Bronshtein I.B., Shuster A.M., Gromova I.I., Krashuk O.A., Geva O.N., Alekberova Z.S., Gabibov A.G. Anti-idiotypic antibodies to topoisomerase I in serum from patients with autoimmune diseases. Dokl. Akad. Nauk SSSR. 318:1991;1496.
5. Bronshtein I.B., Shuster A.M., Gololobov G.V., Gromova I.I., Kvashuk O.A., Belostotskaya K.M., Alekberova Z.S., Prokaeva T.B., Gabibov A.G. DNA-specific antiidiotypic antibodies in the sera of patients with autoimmune diseases. FEBS Lett. 314:1992;259.
6. D'Arpa P., White-Cooper H., Cleveland D.W., Rothfield N.F., Earnshaw W.C. Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients. Arthritis Rheum. 33:1991;1501.
7. Friboulet A., Avalle B., Débat H., Thomas D. A possible role of catalytic antibodies in metabolism. Immunol. Today. 20:1999;474.
8. Gabibov A.G., Gololobov G.V., Makarevich O.I., Schourov D.V., Chernova E.A., Yadav R.P. DNA-hydrolyzing autoantibodies. Appl. Biochem. Biotechnol. 47:1994;293.
9. Gabibov A.G., Kozyr A.V., Kolesnikov A.V. Disease association and cytotoxic effects of DNA-hydrolyzing autoantibodies. Chem. Immunol. 77:2000;130.
10. Harlow E., Lane D. Antibodies. A Laboratory Manual. 1988;Cold Spring Harbor Press, Cold Spring, NY.
11. Hifumi E., Okamoto Y., Uda T. How and why 41S-2 antibody subunits acquire the ability to catalyze decomposition of the conserved sequence of gp41 of HIV-1. Appl. Biochem. Biotechnol. 83:2001;209.
12. Izadyar L., Friboulet A., Rémy M.H., Roseto A., Thomas D. Monoclonal anti-idiotypic antibodies as functional internal images of enzyme active sites: production of a catalytic antibody with a cholinesterase activity. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8876.
13. Karlstrom A., Zhong G., Rader C., Larsen N.A., Heine A., Fuller R., List B., Tanaka F., Wilson I.A., Barbas C.F. 3rd, Lerner R.A. Using antibody catalysis to study the outcome of multiple evolutionary trials of a chemical task. Proc. Natl. Acad. Sci. U. S. A. 97:2000;3878.
14. Knight J.G., Adams D.D., Purves H.D. The genetic contribution of the NZB mouse to the renal disease of the NZB×NZW hybrid. Clin. Exp. Immunol. 28:1977;352.
15. Kolesnikov A.V., Kozyr A.V., Alexandrova E.S., Koralewski F., Demin A.V., Titov M.I., Avalle B., Tramontano A., Paul S., Thomas D., Gabibov A.G., Friboulet A. Enzyme mimicry by the antiidiotypic antibody approach. Proc. Natl. Acad. Sci. U. S. A. 97:2000;13526.
16. Kozyr A.V., Kolesnikov A.V., Aleksandrova E.S., Sashchenko L.P., Gnuchev N.V., Favorov P.V., Kotelnikov M.A., Iakhnina E.I., Astsaturov I.A., Prokaeva T.B., Alekberova Z.S., Suchkov S.V., Gabibov A.G. Novel functional activities of anti-DNA autoantibodies from sera of patients with lymphoproliferative and autoimmune diseases. Appl. Biochem. Biotechnol. 75:2000;45.
17. Kozyr A.V., Sashchenko L.P., Kolesnikov A.V., Zelenova N.A., Khaidukov S.V., Ignatova A.N., Bobik T.V., Gabibov A.G., Alekberova Z.S., Suchkov S.V., Gnuchev N.V. Anti-DNA autoantibodies reveal toxicity to tumor cell lines. Immunol. Lett. 80:2002;41.
18. Lacroix-Desmazes S., Moreau A., Sooryanarayana K., Bonnemain C., Stieltjes N., Pashov A., Sultan Y., Hoebeke J., Kazatchkine M.D., Kaveri S.V. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat. Med. 5:1999;1044.
19. Li L., Paul S., Tyutyulkova S., Kazatchkine M.D., Kaveri S. Catalytic activity of anti-thyroglobulin antibodies. J. Immunol. 154:2000;3328.
20. March S.C., Parikh I., Cuatrecasas P. A simplified method for cyanogen bromide activation of agarose for affinity chromatography. Anal. Biochem. 60:1974;149.
21. Matsuura K., Yamamoto K., Sinohara H. Amidase activity of human Bence Jones proteins. Biochem. Biophys. Res. Commun. 204:1994;57.
22. Mei S., Mody B., Eklund S.H., Paul S. Vasoactive intestinal peptide hydrolysis by antibody light chains. J. Biol. Chem. 266:1991;15571.
23. Paterson P.Y., Day E.D., Whitacre C.C., Berenberg R.A., Harter D.H. Endogenous myelin basic protein-serum factors (MBP-SFs) and anti-MBP antibodies in humans. Occurrence in sera of clinically well subjects and patients with multiple sclerosis. J. Neurol. Sci. 52:1981;37.
24. Paul S. Mechanism and functional role of antibody catalysis. Appl. Biochem. Biotechnol. 75:1998;13.
25. Paul S., Volle D.J., Beach C.M., Johnson D.R., Powell M.J., Massey R.J. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science. 244:1989;1158.
26. Paul S., Li L., Kalaga R., Wilkins-Stevens P., Stevens F.J., Solomon A. Natural catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL fragment. J. Biol. Chem. 270:1995;15257.
27. Rose N.R., Beisel K.W., Herskowitz A., Neu N., Wolfgram L.J., Alvarez F.L., Traystman M.D., Craig S.W. Cardiac myosin and autoimmune myocarditis. Ciba Found. Symp. 129:1987;3.
28. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: a Laboratory Manual. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
29. Sashchenko L.P., Khaidukov S.V., Kozyr A.V., Luk'yanova T.I., Gabibov A.G., Suchkov S.V., Bobik T.V., Alekberova Z.S., Gnuchev N.V. Caspase-dependent cytotoxicity of anti-DNA autoantibodies. Dokl. Biochem. Biophys. 380:2001;313.
30. Schourov D.V., Gololobov G.V., Makarevich O.I., Yadav R.P., Chernova E.A., Nevinsky G.A., Prokaeva T.B., Alekberova Z.S., Gabibov A.G. DNA-hydrolyzing autoantibodies in autoimmune pathologies. Ann. N.Y. Acad. Sci. 750:1995;255.
31. Shabat D., Lode H.N., Pertl U., Reisfeld R.A., Rader C., Lerner R.A., Barbas C.F. 3rd In vivo activity in a catalytic antibody-prodrug system: antibody catalyzed etoposide prodrug activation for selective chemotherapy. Proc. Natl. Acad. Sci. U. S. A. 98:2001;7528.
32. Shuster A.M., Gololobov G.V., Kvashuk O.A., Bogomolova A.E., Smirnov I.V., Gabibov A.G. DNA hydrolyzing autoantibodies. Science. 256:1992;665.
33. Sidorik L.L., Rodnin N.V., Bobyk V.I., Ryabenko D.V., Veberov A.V., Tkachenko Y.T., Matsuka G.Kh. Investigation of autoantibodies directed against tissue-specific myocardial antigens in dilated cardiomyopathy. Biopolym. Cell (Kiev). 11:1995;81.
34. Sun J., Takahashi N., Kakinuma H., Nishi Y. Molecular evolution of catalytic antibodies in autoimmune mice. J. Immunol. 167:2001;5775.
35. Takahashi N., Kakinuma H., Hamada K., Shimazaki K., Yamasaki Y., Matsushita H., Nishi Y. Improved generation of catalytic antibodies by MRL/MPJ-lpr/lpr autoimmune mice. J. Immunol. Methods. 235:2001;113.
36. Tawfik D.S., Chap R., Green B.S., Sela M., Eshhar Z. Unexpectedly high occurrence of catalytic antibodies in MRL/lpr and SJL mice immunized with a transition-state analog: is there a linkage to autoimmunity? Proc. Natl. Acad. Sci. U. S. A. 92:1995;2145.
37. Theofilopoulos A.N., Dixon F.J. Murine models of systemic lupus erythematosus. Adv. Immunol. 37:1985;269.
38. Torchilin V.P., Iakoubov L.Z., Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol. 22:2001;424.
39. Voss E.W. Jr., Workman C.J., Mummert M.E. Detection of protease activity using a fluorescence-enhancement globular substrate. Biotechniques. 20:1996;286.